EU Funds RNA Vaccine Project for Liver Cancer
An international consortium led by Cima Universidad de Navarra will develop personalized RNA vaccines targeting hepatocellular carcinoma.
Updated on Nov. 9, 2026 in Cancer

The European Innovation Council selected the ADVANCE project in its EIC Pathfinder Open 2026 call for proposals. The 3.8 million euro project studies targeted lipid nanoparticles loaded with RNA vaccines to treat hepatocellular carcinoma, the most common form of liver cancer.
Why it matters
Most hepatocellular carcinoma cases are diagnosed at advanced stages, and the project's researchers link rising incidence to increased alcohol consumption and obesity. The project aims to demonstrate proof of concept for efficacy through preclinical validation.
The ADVANCE project carries a budget of 3.8 million euros, while hepatocellular carcinoma incidence is projected to exceed one million cases annually in the coming decade. Efficacy in humans remains unproven, as the project seeks only preclinical in vitro and in vivo validation.
The players
Cima Universidad de Navarra
A research center in Spain leading the ADVANCE consortium and coordinated by Dr. Puri Fortes.
European Innovation Council
An EU funding body that selected the ADVANCE project through its EIC Pathfinder Open 2026 call.
The details
The consortium, led by Dr. Puri Fortes of Cima Universidad de Navarra, includes Certest Biotec, the Princess Máxima Center for Pediatric Oncology, the Netherlands Cancer Institute and Goethe University Frankfurt. The project uses tumor-specific peptides derived from small proteins as 'dark' antigens, based on the idea that cellular stress selectively alters RNA translation in cancer cells.
Timeline
2026: The European Innovation Council selected the ADVANCE project in its EIC Pathfinder Open 2026 call.
Coming decade: Hepatocellular carcinoma incidence is projected to exceed one million cases annually.
Big Picture
The project extends the mRNA platform behind COVID-19 vaccines into personalized cancer therapy, targeting liver tumors where most cases are caught late. Its success would test whether that technology transfers from infectious disease to solid tumors.
Personalized RNA vaccines, if validated, could eventually offer a new treatment option for people with advanced liver cancer. The approach remains preclinical, so no clinical access is available yet.
The takeaway
Liver cancer risk factors such as alcohol use and obesity are modifiable, and reducing them remains one of the most practical steps readers can take. Research into personalized vaccines is promising but still years from patient use.
Further reading
Explore more on Cancer research and treatment developments.



